FDA Approves New Therapy for Rare Form of Blood Cancers Called Myelodysplastic Syndromes
The U.S. Food and Drug Administration recently approved Tibsovo (ivosidenib)Â for the treatment of adult patients with relapsed or refractory (R/R) myelodysplastic syndromes (MDS) with an isocitrate dehydrogenase-1 (IDH1) mutation as …
FDA Approves New Therapy for Rare Form of Blood Cancers Called Myelodysplastic Syndromes Read More